Ameliorative Potential of Resveratrol on Experimentally-Induced Seizures

Ahmed M Kabel^{1, 2,}

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

²Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Cite this paper:
Ahmed M Kabel. Ameliorative Potential of Resveratrol on Experimentally-Induced Seizures. International Journal of Clinical and Experimental Neurology. 2014; 2(2):16-23. doi: 10.12691/ijcen-2-2-1

Abstract

The aim of this study was to investigate the potential enhancement effects of resveratrol on the anticonvulsant effect of diazepam in pilocarpine induced seizures in rats. This study was carried out in 50 male albino rats subdivided into five equal groups; group1 received saline 0.9 % intraperitoneally and served as the control group; group 2 received pilocarpine; group 3 received resveratrol 30 min prior to pilocarpine; group 4 received diazepam 30 min prior to pilocarpine; group 5 received resveratrol/ diazepam combination 30 min prior to pilocarpine. Then, animals were decapitated and the hippocampus was collected and homogenized for determination of tissue interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), nitric oxide (NO), malondialdehyde level (MDA), superoxide dismutase (SOD) and catalase (CAT) activity. Resveratrol/diazepam combination produced significant decrease in tissue cytokines, NO and MDA while produced significant increase in tissue SOD and CAT activity compared to the use of diazepam alone. Also, this combination produced significant delay in the onset of convulsions and significant decrease in the mortality rates compared to the use of diazepam alone. In conclusion, resveratrol potentiates the anticonvulsant effect of diazepam and this may be beneficial in lowering the incidence of resistance to diazepam and also may allow reduction of its dose and side effects.

Keywords:
resveratrol diazepam pilocarpine seizures

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Zhao Q, Luo JJ (2014). Epilepsy in Elderly. Brain Disord Ther; 3: 115.
[2]	Goldenberg MM (2010). Overview of Drugs Used For Epilepsy and Seizures. Pharmacy and Therapeutics; 35(7): 392-415.
[3]	Beghi M, Savica R, Beghi E, Nobili A, Garattini L (2009) Utilization and costs of antiepileptic drugs in the elderly: still an unsolved issue. Drugs Aging; 26: 157-168.
[4]	Gomez-Ibañeza A, Gasca-Salasa C, Urrestarazuc E, Viteri C (2013). Clinical phenotypes within non-surgical patients with mesial temporal lobe epilepsy caused by hippocampal sclerosis based on response to antiepileptic drugs. Seizure; 22 (1): 20-23.
[5]	Marchi N, Fan Q, Ghosh C, FazioV, Bertolini F, Betto G, Batra A, Carlton E, Najm I, Granata T, Janigro D (2009). Antagonism of Peripheral Inflammation Reduces the Severity of Status Epilepticus. Neurobiol Dis; 33(2): 171-181.
[6]	Reddy DS, Kuruba R (2013). Experimental Models of Status Epilepticus and Neuronal Injury for Evaluation of Therapeutic Interventions. Int J Mol Sci; 14(9): 18284-18318.
[7]	Aguiar CCT, Almeida AB, Araújo PVP, et al., (2012). Oxidative Stress and Epilepsy: Literature Review. Oxidative Medicine and Cellular Longevity; vol. 2012, article ID 795259.
[8]	Devi PU, Manocha A, Vohora D (2008). Seizures, antiepileptics, antioxidants and oxidative stress: an insight for researchers. Expert Opin Pharmacother; 9 (18): 3169-3177.
[9]	Vezzani A, French J, Bartfai T, Baram TZ (2011). The role of inflammation in epilepsy. Nat Rev Neurol; 7: 31-40
[10]	Järvelä JT, Lopez-Picon FR, Plysjuk A, Ruohonen S, Holopainen IE (2011). Temporal profiles of age-dependent changes in cytokine mRNA expression and glial cell activation after status epilepticus in postnatal rat hippocampus. Journal of Neuroinflammation; 8: 29.
[11]	Rao RS, Prakash A, Medhi B (2009). Role of different cytokines and seizure susceptibility: A new dimension towards epilepsy research. Indian Journal of Experimental Biology; 47: 625-634.
[12]	Brisdelli F, D'Andrea G, Bozzi A (2009). Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab; 10(6):530-46.
[13]	Ramprasath VR, Jones PJH (2010). Anti-atherogenic effects of resveratrol. European Journal of Clinical Nutrition; 64: 660-668.
[14]	Venugopal R, Liu RH (2012). Phytochemicals in diets for breast cancer prevention: The importance of resveratrol and ursolic acid. Food Science and Human Wellness; 1(1): 1-13.
[15]	Shetty AK (2011). Promise of resveratrol for easing status epilepticus and epilepsy. Pharmacology and Therapeutics; 131(3): 269-286.
[16]	Gupta YK, Chaudhary G, Srivastava AK (2002). Protective Effect of Resveratrol against Pentylenetetrazole-Induced Seizures and Its Modulation by an Adenosinergic System. Pharmacology; 65 (3): 170-4.
[17]	Serdiuk SE, Gmiro VE (2012). Adrenaline potentiates antiepileptic but not sedative action of diazepam in rats. Ross Fiziol Zh Im I M Sechenova.; 98(2):236-41.
[18]	Wilhelm EA, Jesse CR, Bortolatto CF, Nogueira CW, Savegnago LA (2009). Anticonvulsant and antioxidant effects of 3-alkynyl selenophene in 21-day-old rats on pilocarpine model of seizures. Brain Res Bull; 79(5): 281-7.
[19]	Turski WA, Czuczwar SJ, Kleinrok Z, Turski L (1983). Cholinomimetics produce seizures and brain damage in rats. Experientia; 39:1408-1411.
[20]	Kabel AM, Abdel-Rahman MN, El-Sisi Ael-D, Haleem MS, Ezzat NM, El Rashidy MA (2013). Effect of atorvastatin and methotrexate on solid Ehrlich tumor. Eur J Pharmacol; 713 (1-3): 47-53.
[21]	Alderton WK, Cooper CE, Knowles RG (2001). Nitric oxide synthases: structure, function and inhibition. Biochem J; 357: 593-615.
[22]	Draper HH, Hadley M (1990). Malondialdehyde determination as index of lipid peroxidation. Methods in Enzymology; 186: 421-431.
[23]	Tsai HL, Chang CN, Chang SJ (2010). The effects of pilocarpine-induced status epilepticus on oxidative stress/damage in developing animals. Brain and Development; 32 (1): 25-31.
[24]	Aebi H (1984). Catalase in vitro. Methods Enzymol; 105: 121-6.
[25]	Acharya MM, Hattiangady B, Shetty AK (2008). Progress in Neuroprotective Strategies for Preventing Epilepsy. Prog Neurobiol; 84(4): 363-404.
[26]	Jope RS, Morrisett RA, Snead OC (1986). Characterization of lithium potentiation of pilocarpine-induced status epilepticus in rats. Exp Neurol; 91: 471-480.
[27]	Curia G, Longo D, Biagini G, Jones RSG, Avoli M (2008). The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods; 172(2-4): 143-157.
[28]	Tomé AR, Ferreira PMP, Freitas RM (2010). Inhibitory action of antioxidants (ascorbic acid or α-tocopherol) on seizures and brain damage induced by pilocarpine in rats. Arquivos de Neuro-Psiquiatria; 68(3): 355-361.
[29]	Marchi N, Oby E, Batra A, Uva L, De Curtis M, Hernandez N, Van Boxel Dezaire A, Najm I, Janigro D (2007). In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia; 48:1934-1946.
[30]	Harvey L, Boksa P (2012). Prenatal and postnatal animal models of immune activation: Relevance to a range of neurodevelopmental disorders. Developmental Neurobiology; 72 (10): 1335-1348
[31]	Galic MA, Riazi K, Heida JG, Mouihate A, Fournier NM, Spencer SJ, Kalynchuk LE, Teskey GC, Pittman QJ (2008). Postnatal inflammation increases seizure susceptibility in adult rats. J Neurosci ; 28: 6904-6913.
[32]	Riazi K, Galic MA, Kuzmiski JB, Ho W, Sharkey KA, Pittman QJ (2008). Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci USA; 105: 17151-17156.
[33]	Vezzani A (2009). Pilocarpine-Induced Seizures Revisited: What Does the Model Mimic?. Epilepsy Curr; 9 (5): 146-148.
[34]	Vezzani A, Balosso S, Ravizza T (2008). The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun; 22: 797-803.
[35]	Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A (2008). Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis; 29: 142-160.
[36]	Hrncic D, Rasic-Markovic A, Bjekic-Macut J, et al., (2012). Gaseous neurotransmitter nitric oxide: Its role in experimental models of epilepsy. Arch Biol Sci; 64 (3): 1207-1216.
[37]	Dos Santos PS, Costa JP, Tomé Ada R, Saldanha GB, de Souza GF, Feng D, de Freitas RM (2011). Oxidative stress in rat striatum after pilocarpine-induced seizures is diminished by alpha-tocopherol. Eur J Pharmacol; 668(1-2): 65-71.
[38]	Lehtim¨aki KA, Ker¨anen T, Huhtala H (2004). Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration. Journal of Neuroimmunology; 152(1-2): 121-125.
[39]	Uludag IF, Bilgin S, Zorlu Y, Tuna G, Kirkali G (2013). Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure; 22 (6): 457-461.
[40]	Wu Z, Xu Q, Zhang L, Kong D, Ma R, Wang L (2009). Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res; 34(8): 1393-400.
[41]	Mokni M, Elkahoui S, Limam F, Amri A, Aouani E (2007). Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat Neurochem Res; 32: 981-987.
[42]	Grissa KA, Mornagui B, Aouani 1E, Hammami M, Gharbi N, Kamoun A, El-fazaa S (2006). Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol & Alcoholism; 41(3): 236-239.
[43]	Quincozes-Santos A, Bobermin LD, Wajner M, Souza DO, Gonçalves CA, Gottfried C (2013). Resveratrol Protects C6 Astrocyte Cell Line against Hydrogen Peroxide-Induced Oxidative Stress through Heme Oxygenase 1. PLoS ONE; 8(5): e64372.
[44]	Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T (2005). Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol; 5: 185-193.
[45]	Lu X, Ma L, Ruan L, Kong Y, Mou H, Zhang Z, Wang Z, Wang JM, Le Y (2010). Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation; 7: 46.
[46]	Pitkanen A, Kharatishvili I, Narkilahti S, Lukasiuk K, Nissinen J (2005). Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res; 63: 27-42.
[47]	Bianchi MT (2010). Context Dependent Benzodiazepine Modulation of GABAA Receptor Opening Frequency. Curr Neuropharmacol; 8 (1): 10-17.
[48]	Richter L, de Graaf C, Sieghart W, Varagic Z, Mörzinger M, de Esch IJ, Ecker GF, Ernst M (2012). Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. Nat Chem Biol; 8 (5): 455-464.
[49]	Paul V, Subramanian EH, Rajasekaran K (2001). Pharmacological evidence for a role of gamma-aminobutyric acid A receptor mechanism in modulating nitric oxide synthase activity in rat brain. Neurochem Int; 38(3): 209-11.
[50]	Seçkin S, Alsancak S, Başaran-Küçükgergin C, Uysal M (2007). The effect of chronic diazepam administration on lipid peroxidation and Ca2+-ATPase activity in rat liver. Acta Biol Hung; 58(4): 441-3.